Individuals with fast nicotine metabolism typically smoke more and thus have a greater risk for smoking-induced diseases. Further, the efficacy of smoking cessation pharmacotherapy is dependent on the rate of nicotine metabolism. Our objective was to use nicotine metabolite ratio (NMR), an established biomarker of nicotine metabolism rate, in a genome-wide association study (GWAS) to identify novel genetic variants influencing nicotine metabolism. A heritability estimate of 0.81 (95% CI 0.70–0.88) was obtained for NMR using monozygotic and dizygotic twins of the FinnTwin cohort. We performed a GWAS in cotinine-verified current smokers of three Finnish cohorts (FinnTwin, Young Finns Study, FINRISK2007), followed by a meta-analysis of 1518 subjects, and annotated the genome-wide significant SNPs with methylation quantitative loci (meQTL) analyses. We detected association on 19q13 with 719 SNPs exceeding genome-wide significance within a 4.2 Mb region. The strongest evidence for association emerged for CYP2A6 (min p = 5.77E-86, in intron 4), the main metabolic enzyme for nicotine. Other interesting genes with genome-wide significant signals included CYP2B6, CYP2A7, EGLN2, and NUMBL. Conditional analyses revealed three independent signals on 19q13, all located within or in the immediate vicinity of CYP2A6. A genetic risk score constructed using the independent signals showed association with smoking quantity (p = 0.0019) in two independent Finnish samples. Our meQTL results showed that methylation values of 16 CpG sites within the region are affected by genotypes of the genome-wide significant SNPs, and according to causal inference test, for some of the SNPs the effect on NMR is mediated through methylation. To our knowledge, this is the first GWAS on NMR. Our results enclose three independent novel signals on 19q13.2. The detected CYP2A6 variants explain a strikingly large fraction of variance (up to 31%) in NMR in these study samples. Further, we provide evidence for plausible epigenetic mechanisms influencing NMR.
References
[1]
Moss HB, Chen CM, Yi HY. Measures of substance consumption among substance users, DSM-IV abusers, and those with DSM-IV dependence disorders in a nationally representative sample. J Stud Alcohol Drugs. 2012;73(5): 820–28. pmid:22846246 doi: 10.15288/jsad.2012.73.820
[2]
Ross S, Peselow E. The neurobiology of addictive disorders. Clin Neuropharmacol. 2009;32(5): 269–76. pmid:19834992 doi: 10.1097/wnf.0b013e3181a9163c
[3]
Dempsey D, Tutka P, Jacob P 3rd, Allen F, Schoedel K, Tyndale RF, et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther. 2004;76(1): 64–72. pmid:15229465 doi: 10.1016/j.clpt.2004.02.011
[4]
Strasser AA, Benowitz NL, Pinto AG, Tang KZ, Hecht SS, Carmella SG, et al. Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level. Cancer Epidemiol Biomarkers Prev. 2011;20(2): 234–38. doi: 10.1158/1055-9965.EPI-10-0674. pmid:21212060
[5]
Ray R, Tyndale RF, Lerman C. Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. J Neurogenet. 2009;23(3): 252–61. doi: 10.1080/01677060802572887. pmid:19169923
[6]
Ho MK, Tyndale RF. Overview of the pharmacogenomics of cigarette smoking. Pharmacogenomics J. 2007;7(2): 81–98. pmid:17224913 doi: 10.1038/sj.tpj.6500436
[7]
Benowitz NL. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol. 2009;49: 57–71. doi: 10.1146/annurev.pharmtox.48.113006.09474？2. pmid:18834313
[8]
Grando SA. Connections of nicotine to cancer. Nat Rev Cancer. 2014;14(6): 419–29. doi: 10.1038/nrc3725. pmid:24827506
[9]
Hukkanen J, Jacob P 3rd, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev. 2005;57(1): 79–115. pmid:15734728 doi: 10.1124/pr.57.1.3
[10]
Yamazaki H, Inoue K, Hashimoto M, Shimada T. Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999;73(2): 65–70. pmid:10350185 doi: 10.1007/s002040050588
[11]
Miksys S, Lerman C, Shields PG, Mash DC, Tyndale RF. Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology. 2003;45(1): 122–32. pmid:12814665 doi: 10.1016/s0028-3908(03)00136-9
[12]
Garcia KL, Coen K, Miksys S, Lê AD, Tyndale RF. Effect of Brain CYP2B Inhibition on Brain Nicotine Levels and Nicotine Self-Administration. Neuropsychopharmacology. 2015;40(8):1910–8. doi: 10.1038/npp.2015.40. pmid:25652250
Thorgeirsson TE, Gudbjartsson DF, Surakka I, Vink JM, Amin N, Geller F, et al. Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat Genet. 2010;42(5): 448–53. doi: 10.1038/ng.573. pmid:20418888
[15]
Benowitz NL, Hukkanen J, Jacob P 3rd. Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacol. 2009;192: 29–60. doi: 10.1007/978-3-540-69248-5_2. pmid:19184645
[16]
Swan GE, Lessov-Schlaggar CN, Bergen AW, He Y, Tyndale RF, Benowitz NL. Genetic and environmental influences on the ratio of 3'hydroxycotinine to cotinine in plasma and urine. Pharmacogenet Genomics. 2009;19(5): 388–98. doi: 10.1097/FPC.0b013e32832a404f. pmid:19300303
[17]
Chenoweth MJ, Novalen M, Hawk LW Jr, Schnoll RA, George TP, Cinciripini PM, et al. Known and novel sources of variability in the nicotine metabolite ratio in a large sample of treatment-seeking smokers. Cancer Epidemiol Biomarkers Prev. 2014;23(9): 1773–82. doi: 10.1158/1055-9965.EPI-14-0427. pmid:25012994
[18]
Higashi E, Fukami T, Itoh M, Kyo S, Inoue M, Yokoi T, et al. Human CYP2A6 is induced by estrogen via estrogen receptor. Drug Metab Dispos. 2007;35(10): 1935–41. pmid:17646279 doi: 10.1124/dmd.107.016568
[19]
Lerman C, Tyndale R, Patterson F, Wileyto EP, Shields PG, Pinto A, et al. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin Pharmacol Ther. 2006;79(6):600–8. pmid:16765148 doi: 10.1016/j.clpt.2006.02.006
[20]
Patterson F, Schnoll RA, Wileyto EP, Pinto A, Epstein LH, Shields PG, et al. Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clin Pharmacol Ther. 2008;84(3): 320–25. doi: 10.1038/clpt.2008.57. pmid:18388868
[21]
Schnoll RA, Patterson F, Wileyto EP, Tyndale RF, Benowitz N, Lerman C. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol Biochem Behav. 2009;92(1): 6–11. doi: 10.1016/j.pbb.2008.10.016. pmid:19000709
[22]
Lerman C, Schnoll RA, Hawk LW Jr, Cinciripini P, George TP, Wileyto EP, et al. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2015;3(2): 131–38. doi: 10.1016/S2213-2600(14)70294-2. pmid:25588294
[23]
Kettunen J, Tukiainen T, Sarin AP, Ortega-Alonso A, Tikkanen E, Lyytik？inen LP, et al. Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nat Genet. 2012;44(3): 269–76. doi: 10.1038/ng.1073. pmid:22286219
[24]
Demirkan A, Henneman P, Verhoeven A, Dharuri H, Amin N, van Klinken JB, et al. Insight in genome-wide association of metabolite quantitative traits by exome sequence analyses. PLoS Genet. 2015;11(1): e1004835. doi: 10.1371/journal.pgen.1004835. pmid:25569235
[25]
Kaprio J. Twin studies in Finland 2006. Twin Res Hum Genet. 2006;9(6): 772–77. pmid:17254406 doi: 10.1375/183242706779462778
[26]
Kaprio J. The Finnish Twin Cohort Study: an update. Twin Res Hum Genet. 2013;16(1): 157–62. doi: 10.1017/thg.2012.142. pmid:23298696
[27]
Latvala A, Tuulio-Henriksson A, Dick DM, Vuoksimaa E, Viken RJ, Suvisaari J, et al. Genetic origins of the association between verbal ability and alcohol dependence symptoms in young adulthood. Psychol Med. 2011;41(3): 641–51. doi: 10.1017/S0033291710001194. pmid:20529418
[28]
Dick DM, Aliev F, Viken R, Kaprio J, Rose RJ. Rutgers alcohol problem index scores at age 18 predict alcohol dependence diagnoses 7 years later. Alcohol Clin Exp Res. 2011;35(5): 1011–4. doi: 10.1111/j.1530-0277.2010.01432.x. pmid:21323682
[29]
Raitakari OT, Juonala M, R？nnemaa T, Keltikangas-J？rvinen L, R？s？nen L, Pietik？inen M, et al. Cohort profile: the cardiovascular risk in Young Finns Study. Int J Epidemiol. 2008;37(6): 1220–6. doi: 10.1093/ije/dym225. pmid:18263651
[30]
Lea RA, Dickson S, Benowitz NL. Within-subject variation of the salivary 3HC/COT ratio in regular daily smokers: prospects for estimating CYP2A6 enzyme activity in large-scale surveys of nicotine metabolic rate. J Anal Toxicol. 2006;30(6): 386–89. pmid:16872570 doi: 10.1093/jat/30.6.386
[31]
Borodulin K, Vartiainen E, Peltonen M, Jousilahti P, Juolevi A, Laatikainen T, et al. Forty-year trends in cardiovascular risk factors in Finland. Eur J Public Health. 2015;25(3):539–46. doi: 10.1093/eurpub/cku174. pmid:25422363
[32]
Loukola A, Wedenoja J, Keskitalo-Vuokko K, Broms U, Korhonen T, Ripatti S, et al. Genome-wide association study on detailed profiles of smoking behavior and nicotine dependence in a twin sample. Mol Psychiatry. 2014;19(5): 615–24. doi: 10.1038/mp.2013.72. pmid:23752247
[33]
St Helen G, Novalen M, Heitjan DF, Dempsey D, Jacob P 3rd, Aziziyeh A, et al. Reproducibility of the nicotine metabolite ratio in cigarette smokers. Cancer Epidemiol Biomarkers Prev. 2012;21(7): 1105–14. doi: 10.1158/1055-9965.EPI-12-0236. pmid:22552800
[34]
Broms U, Pennanen M, Patja K, Ollila H, Korhonen T, Kankaanp？？ A, et al. Diurnal Evening Type is Associated with Current Smoking, Nicotine Dependence and Nicotine Intake in the Population Based National FINRISK 2007 Study. J Addict Res Ther. 2012 Jan 25;S2. pii: 002. pmid:22905332 doi: 10.4172/2155-6105.s2-002
[35]
Tanner J-A, Novalen M, Jatlow P, Huestis MA, Murphy SE, Kaprio J, et al. Agreement and association between measures of the nicotine metabolite ratio by different analytical approaches in plasma and urine: Implications for clinical implementation. Cancer Epidemiology, Biomarkers & Prevention, in press
[36]
Delaneau O, Howie B, Cox AJ, Zagury JF, Marchini J. Haplotype estimation using sequencing reads. Am J Hum Genet. 2013;93(4): 687–96. doi: 10.1016/j.ajhg.2013.09.002. pmid:24094745
[37]
Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 2009;5(6): e1000529. doi: 10.1371/journal.pgen.1000529. pmid:19543373
[38]
1000 Genomes Project Consortium, Abecasis GR, Auton A Brooks LD, DePristo MA, Durbin RM, et al. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491(7422): 56–65. doi: 10.1038/nature11632. pmid:23128226
[39]
Neale MC, Boker SM, Xie G, Maes HH (2006). Mx: Statistical Modeling. VCU Box 900126, Richmond, VA 23298: Department of Psychiatry. 7th Edition.
[40]
Silverberg MS, Cho JH, Rioux JD, McGovern DP, Wu J, Annese V, et al. Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nat Genet. 2009;41(2): 216–20. doi: 10.1038/ng.275. pmid:19122664
[41]
Purcell S, Cherny SS, Sham PC. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 2003;19(1): 149–50. pmid:12499305 doi: 10.1093/bioinformatics/19.1.149
[42]
Aulchenko YS, Ripke S, Isaacs A, van Duijn CM. GenABEL: an R library for genome-wide association analysis. Bioinformatics. 2007;23(10): 1294–96. pmid:17384015 doi: 10.1093/bioinformatics/btm108
[43]
Zhou X, Stephens M. Genome-wide efficient mixed-model analysis for association studies. Nat Genet. 2012;44(7): 821–24. doi: 10.1038/ng.2310. pmid:22706312
[44]
Liu JZ, Tozzi F, Waterworth DM, Pillai SG, Muglia P, Middleton L, et al. Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet. 2010;42(5): 436–40. doi: 10.1038/ng.572. pmid:20418889
[45]
Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2): 263–65. pmid:15297300 doi: 10.1093/bioinformatics/bth457
[46]
Aryee MJ, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, Feinberg AP, Hansen KD, et al. Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics. 2014;30(10): 1363–69. doi: 10.1093/bioinformatics/btu049. pmid:24478339
[47]
Naeem H, Wong NC, Chatterton Z, Hong MK, Pedersen JS, Corcoran NM, et al. Reducing the risk of false discovery enabling identification of biologically significant genome-wide methylation status using the HumanMethylation450 array. BMC Genomics. 2014;15: 51. doi: 10.1186/1471-2164-15-51. pmid:24447442
[48]
Bell JT, Pai AA, Pickrell JK, Gaffney DJ, Pique-Regi R, Degner JF, et al. DNA methylation patterns associate with genetic and gene expression variation in HapMap cell lines. Genome Biol. 2011;12(1): R10. doi: 10.1186/gb-2011-12-1-r10. pmid:21251332
[49]
Almli LM, Stevens JS, Smith AK, Kilaru V, Meng Q, Flory J, et al. A genome-wide identified risk variant for PTSD is a methylation quantitative trait locus and confers decreased cortical activation to fearful faces. Am J Med Genet B Neuropsychiatr Genet. 2015;168B(5): 327–36. doi: 10.1002/ajmg.b.32315. pmid:25988933
[50]
Benjamini Y, Hochberg Y. Controlling the false discovery rate—A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society, Series B (Metallurgy) 1995;57(1): 289–300.
Cuellar-Partida G, Renteria ME, MacGregor S. LocusTrack: Integrated visualization of GWAS results and genomic annotation. Source Code Biol Med. 2015;10: 1. doi: 10.1186/s13029-015-0032-8. pmid:25750659
[53]
Dawood N, Vaccarino V, Reid KJ, Spertus JA, Hamid N, Parashar S, et al. Predictors of smoking cessation after a myocardial infarction: the role of institutional smoking cessation programs in improving success. Arch Intern Med. 2008;168(18): 1961–67. doi: 10.1001/archinte.168.18.1961. pmid:18852396
[54]
Hartmann-Boyce J, Stead LF, Cahill K, Lancaster T. Efficacy of interventions to combat tobacco addiction: Cochrane update of 2012 reviews. Addiction. 2013;108(10): 1711–21. doi: 10.1111/add.12291. pmid:23834141
[55]
Oscarson M, McLellan RA, Asp V, Ledesma M, Bernal Ruiz ML, Sinues B, et al. Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity. Hum Mutat. 2002;20(4): 275–83. pmid:12325023 doi: 10.1002/humu.10126
[56]
Benowitz NL, Swan GE, Jacob P 3rd, Lessov-Schlaggar CN, Tyndale RF. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clin Pharmacol Ther. 2006;80(5): 457–67. pmid:17112802 doi: 10.1016/j.clpt.2006.08.011
[57]
Nakajima M, Fukami T, Yamanaka H, Higashi E, Sakai H, Yoshida R, et al. Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther. 2006;80(3): 282–97. pmid:16952495 doi: 10.1016/j.clpt.2006.05.012
[58]
Dempsey DA, St Helen G, Jacob P 3rd, Tyndale RF, Benowitz NL. Genetic and pharmacokinetic determinants of response to transdermal nicotine in white, black, and Asian nonsmokers. Clin Pharmacol Ther. 2013;94(6): 687–94. doi: 10.1038/clpt.2013.159. pmid:23933970
[59]
Fukami T, Nakajima M, Higashi E, Yamanaka H, Sakai H, McLeod HL, et al. Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity. Drug Metab Dispos. 2005;33(8): 1202–10. pmid:15900015 doi: 10.1124/dmd.105.004994
[60]
Al Koudsi N, Mwenifumbo JC, Sellers EM, Benowitz NL, Swan GE, Tyndale RF. Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics. Eur J Clin Pharmacol. 2006;62(6): 481–84. pmid:16758265 doi: 10.1007/s00228-006-0113-3
[61]
Hofmann MH, Blievernicht JK, Klein K, Saussele T, Schaeffeler E, Schwab M, et al. Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. J Pharmacol Exp Ther. 2008;325(1): 284–92. doi: 10.1124/jpet.107.133306. pmid:18171905
[62]
Bloom AJ, Baker TB, Chen LS, Breslau N, Hatsukami D, Bierut LJ, et al. Variants in two adjacent genes, EGLN2 and CYP2A6, influence smoking behavior related to disease risk via different mechanisms. Hum Mol Genet. 2014;23(2): 555–61. doi: 10.1093/hmg/ddt432. pmid:24045616
[63]
Zhong W, Jiang MM, Weinmaster G, Jan LY, Jan YN. Differential expression of mammalian Numb, Numblike and Notch1 suggests distinct roles during mouse cortical neurogenesis. Development. 1997;124(10): 1887–97. pmid:9169836
[64]
Yingjie L, Jian T, Changhai Y, Jingbo L. Numblike regulates proliferation, apoptosis, and invasion of lung cancer cell. Tumour Biol. 2013;34(5): 2773–80. doi: 10.1007/s13277-013-0835-7. pmid:23681800
[65]
Vaira V, Faversani A, Martin NM, Garlick DS, Ferrero S, Nosotti M, et al. Regulation of lung cancer metastasis by Klf4-Numb-like signaling. Cancer Res. 2013;73(8): 2695–2705. doi: 10.1158/0008-5472.CAN-12-4232. pmid:23440423
Maemura K, Yoshikawa H, Yokoyama K, Ueno T, Kurose H, Uchiyama K, et al. Delta-like 3 is silenced by methylation and induces apoptosis in human hepatocellular carcinoma. Int J Oncol. 2013;42(3): 817–22. doi: 10.3892/ijo.2013.1778. pmid:23337976
[72]
Fragkiadaki P, Soulitzis N, Sifakis S, Koutroulakis D, Gourvas V, Vrachnis N, et al. Downregulation of notch signaling pathway in late preterm and term placentas from pregnancies complicated by preeclampsia. PLoS One. 2015;10(5): e0126163. doi: 10.1371/journal.pone.0126163. pmid:25962154
